AU2012254093B2 - Effective amounts of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo(2,3-b)indol-5-yl phenylcarbamate and methods thereof - Google Patents

Effective amounts of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo(2,3-b)indol-5-yl phenylcarbamate and methods thereof Download PDF

Info

Publication number
AU2012254093B2
AU2012254093B2 AU2012254093A AU2012254093A AU2012254093B2 AU 2012254093 B2 AU2012254093 B2 AU 2012254093B2 AU 2012254093 A AU2012254093 A AU 2012254093A AU 2012254093 A AU2012254093 A AU 2012254093A AU 2012254093 B2 AU2012254093 B2 AU 2012254093B2
Authority
AU
Australia
Prior art keywords
compound
subject
administering
another embodiment
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012254093A
Other languages
English (en)
Other versions
AU2012254093A1 (en
Inventor
Maria Maccecchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Annovis Bio Inc
Original Assignee
QR Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QR Pharma Inc filed Critical QR Pharma Inc
Publication of AU2012254093A1 publication Critical patent/AU2012254093A1/en
Application granted granted Critical
Publication of AU2012254093B2 publication Critical patent/AU2012254093B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2012254093A 2011-03-04 2012-02-28 Effective amounts of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo(2,3-b)indol-5-yl phenylcarbamate and methods thereof Active AU2012254093B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/041,211 US20120225922A1 (en) 2011-03-04 2011-03-04 Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US13/041,211 2011-03-04
PCT/US2012/026984 WO2012154285A1 (en) 2011-03-04 2012-02-28 Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof

Publications (2)

Publication Number Publication Date
AU2012254093A1 AU2012254093A1 (en) 2013-09-26
AU2012254093B2 true AU2012254093B2 (en) 2015-08-06

Family

ID=46753679

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012254093A Active AU2012254093B2 (en) 2011-03-04 2012-02-28 Effective amounts of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo(2,3-b)indol-5-yl phenylcarbamate and methods thereof

Country Status (10)

Country Link
US (9) US20120225922A1 (https=)
EP (1) EP2683242B8 (https=)
JP (2) JP2014513065A (https=)
KR (1) KR20140019361A (https=)
CN (1) CN103582419A (https=)
AU (1) AU2012254093B2 (https=)
BR (1) BR112013022673A2 (https=)
CA (1) CA2829039C (https=)
DK (1) DK2683242T3 (https=)
WO (1) WO2012154285A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
US12042482B2 (en) * 2015-08-14 2024-07-23 Annovis Bio, Inc. Methods of treatment or prevention of acute brain or nerve injuries
US20180338950A1 (en) 2017-05-24 2018-11-29 Qr Pharma, Inc. Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis Via Administration of Posiphen to Healthy or Sick Humans
WO2020061404A1 (en) * 2018-09-21 2020-03-26 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
SG11202103794QA (en) 2018-11-21 2021-05-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing prion expression
WO2021067864A1 (en) * 2019-10-02 2021-04-08 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for treatment of prion disease
WO2022245843A1 (en) * 2021-05-18 2022-11-24 Annovis Bio, Inc. Inhibition of neurological injuries due to infections via administration of butanetap and analogs thereof
EP4486892A2 (en) * 2022-02-28 2025-01-08 Ionis Pharmaceuticals, Inc. Rnai agents of prion expression
WO2024123663A1 (en) * 2022-12-06 2024-06-13 Sri International Antimicrobial compounds
EP4731205A2 (en) * 2023-06-21 2026-04-29 Annovis Bio, Inc. Solid forms of posiphen d-tartrate
WO2025017530A1 (en) 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089746A1 (en) * 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
US20050272804A1 (en) * 2004-06-08 2005-12-08 Axonyx, Inc Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
WO2010117727A2 (en) * 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
US5409948A (en) * 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
CZ297533B6 (cs) 1997-07-09 2007-01-03 Axonyx Použití inhibitorů butyrylcholinesterázy pro léčbu a diagnostiku Alzheimerovy choroby a demence
EP1311272B1 (en) 2000-03-03 2006-11-22 Eisai Co., Ltd. Novel methods using cholinesterase inhibitors
US7153882B2 (en) * 2000-11-02 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
WO2003024450A1 (en) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) * 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20050031651A1 (en) * 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2004087160A1 (en) 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
US20050013869A1 (en) * 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
JP2007529545A (ja) 2004-03-19 2007-10-25 アクソニクス，インコーポレイテッド ダウン症候群の治療法
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
WO2008153884A1 (en) * 2007-06-07 2008-12-18 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastroesophageal reflux disease
JP4690362B2 (ja) * 2007-07-04 2011-06-01 株式会社リコー Ｓｉｍｄ型マイクロプロセッサおよびｓｉｍｄ型マイクロプロセッサのデータ転送方法
US20120225922A1 (en) * 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089746A1 (en) * 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
US20050272804A1 (en) * 2004-06-08 2005-12-08 Axonyx, Inc Methods of delaying Alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a HMG CoA reductase inhibitor
WO2010117727A2 (en) * 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions

Also Published As

Publication number Publication date
DK2683242T3 (da) 2020-07-06
KR20140019361A (ko) 2014-02-14
US20120225922A1 (en) 2012-09-06
US20200375948A1 (en) 2020-12-03
US20200375947A1 (en) 2020-12-03
CN103582419A (zh) 2014-02-12
US11096926B2 (en) 2021-08-24
JP2018076332A (ja) 2018-05-17
EP2683242A4 (en) 2014-09-03
AU2012254093A1 (en) 2013-09-26
US11382893B2 (en) 2022-07-12
US12144798B2 (en) 2024-11-19
US20210093610A1 (en) 2021-04-01
US11376238B2 (en) 2022-07-05
US20170304266A1 (en) 2017-10-26
EP2683242B1 (en) 2020-04-08
US11400075B2 (en) 2022-08-02
US20190381007A1 (en) 2019-12-19
JP2014513065A (ja) 2014-05-29
CA2829039A1 (en) 2012-11-15
WO2012154285A1 (en) 2012-11-15
BR112013022673A2 (pt) 2017-03-28
EP2683242B8 (en) 2020-06-03
US20150374664A1 (en) 2015-12-31
US10383851B2 (en) 2019-08-20
US20220323413A1 (en) 2022-10-13
US20250114330A1 (en) 2025-04-10
CA2829039C (en) 2021-09-14
EP2683242A1 (en) 2014-01-15

Similar Documents

Publication Publication Date Title
US12144798B2 (en) (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
KR102486434B1 (ko) 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
US20050182044A1 (en) Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
US12390448B2 (en) Prevention or of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans
EP2624821B1 (en) Combination therapy for the treatment of depression and other non-infectious diseases
CA2568213C (en) Composition and method for the treatment of tauopathies
CN102365269A (zh) 用于治疗认知缺损的新药物
EP3135280B1 (en) Tranilast for the treatment of cutaneous amyloidosis
EP2275106A1 (en) Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
WO2025008625A1 (en) Danegaptide for use in treating synucleinopathies
JP2025513458A (ja) ヨーグルト中の生体活性分子
EA048644B1 (ru) Способы лечения нейродегенеративных расстройств
MXPA06009306A (en) Combinatorial therapy with an acetylcholinesterase inhibitorand (3ar)-1, 3a, 8-trimethyl-1, 2, 3, 3a, 8, 8a- hexahydropyrrolo[2, 3-b]indol-5- yl phenylcarbamate
HK1175400B (en) Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)